Getting drugs past the brain's own security system is one of biotech's toughest problems. I've found four ASX-listed companies – Telix, Noxopharm, Neurizon and Ceretas – each at a different stage of proving they can cross the blood-brain barrier.
Discretionary retail has had a rough trot as cost-of-living pressures bite, but James picks out three consumer stocks the market may be underestimating, where analysts see real upside from here.
Here are two situations where analysts see the share market under-estimating the changes taking place in the underlying business, and where the potential for a double is real, if the company can execute.
Four ASX-listed mining services companies where analysts believe share prices have yet to catch up with a promising growth outlook.
I look at two ASX-listed ‘microcap’ companies born in Canberra and are taking their expertise to the world.
It is a very esoteric niche on the ASX, but regenerative medicine is a fascinating area. ASX-listed companies PolyNovo, AVITA Medical and AROA Biosurgery all focus on regenerative medicine and soft-tissue repair, targeting severe burns, trauma and complex wounds, using active biological or structural reconstruction.
I went looking for ASX companies that are genuine disruptors trading at attractive prices. I found two global software stars taking on decades-old legacy systems […]
Two beaten-down stocks are showing signs of life, and in both cases, a hard-fought push into the US market is the reason why.
Drones have gone from novelty gadgets to front-line weapons in barely a decade, and the money is following fast. Here's where the ASX fits into that story.
Here are two ASX-listed fund manager "incubators" that look compelling right now.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.